Last reviewed · How we verify
NCT06195813
Asparagus Capsule Consumption and Blood Sugar and Lipids and Oxidative Stress
Phase 2 trial testing Asparagus capsule in Asparagus Capsule Consumption in 44 participants. Completed in 14 September 2023.
14 September 2023
Quick facts
| Lead sponsor | Burapha University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 44 |
| Start date | 20 December 2022 |
| Primary completion | 14 September 2023 |
| Estimated completion | 14 September 2023 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Asparagus capsule
- Placebo capsule
Conditions studied
- Asparagus Capsule Consumption — all drugs for Asparagus Capsule Consumption →
Sponsor
Burapha University
Who can join
Adults 18 to 59, any sex, with Asparagus Capsule Consumption. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Participants were 44 overweight and obese persons, male and female, age 18-59 years. Participants were divided into 2 groups consisting of 23 asparagus capsules and 21 placebo capsules groups. They received health screenings including history taking, mental health questionnaire, and vital signs, height and body weight, body composition, fat distribution measurements and oral glucose tolerance test. Then, a venipuncture was conducted to determine blood glucose, insulin, lipids malondialdehyde and protein carbonyl levels.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of Asparagus Powder Supplementation on Glycemic Control, Lipid Profile, and Oxidative Stress in Overweight and Obese Adults: An Exploratory Randomized Controlled Trial.
Mongraykang J, Padkao T, Boonla O, Teethaisong Y, et al · · 2025 · cited 1× · PMID 41157258 · DOI 10.3390/life15101584
Verify or expand the search:
- PubMed search for NCT06195813
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Burapha University trials
Trials by the same sponsor.
- NCT07056764 — Development of Lung Vibration Equipment · NA · completed
- NCT07495670 — Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients · NA · completed
- NCT07018128 — Expression of Genes Relating Hypertension and Efficacy of 4-7-8 Breathing Control on Reducing Blood Pressure · NA · recruiting
- NCT07500272 — Agreement of Ocular Biometry and Intraocular Lens Power Between OA-2000 and Pentacam AXL in Cataract Patients · completed
- NCT06475222 — Facial Serum and Mask and Ready-to-drink Jelly From Thai Rice · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06195813 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Burapha University
- Last refreshed: 12 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06195813.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing